In the Department of Oral and Maxillofacial Surgery, Gunma University Hospital, relatively large radicular cysts extending over 3 or more teeth are treated with a combination of complete excision, endodontic microsurgery and Er: YAG laser irradiation, whereby favorable outcomes have been achieved. The purpose of this report is to describe our surgical procedure and discuss the therapeutic outcomes.Patients between December 2008 and December 2014 with radicular cysts pathologically extending over 3 or more teeth, who were followed up for 1 year or longer, participated in this study.
In this case report the author illustrates a protocol for post-extraction fullarch rehabilitation produced with the use of computerized virtual treatment planning and guided surgery. In a 74-year old man presenting a failed maxillary attachment-retained removable partial denture, a treatment plan focused on the immediate loading of a post-extraction full-arch prosthesis was developed. Starting from prosthetic analysis a modular scan template for CBCT examination was designed, with a 3D simulation software a protocol for guided implants placement and prosthetic rehabilitation was setup. With the support of this procedure, the author performed the extraction of eight teeth, the placement of eight implants (including extraction sites) with flapless approach, and the immediate load of a provisional screw retained prosthesis. At one year follow-up clinical and radiographic results were stable. In selected cases, this protocol may offer significant advantages, including one-day treatment, reduced post-surgical discomfort and immediate improvement in function and aesthetics.
Background: This article reports the treatment of a 15-year old male patient with anterior open bite and a severely narrowed upper dental arch. The young patient complained of occlusal and masticatory dysfunction due to the anterior open bite and difficulties in breathing normally through his nose. Case report: A posterior crossbite was present on both sides. For the correction of the posterior cross-bite, a surgically assisted rapid maxillary expansion and a presurgical straight wire multibracket tooth alignment was applied. The treatment plan included Le Fort I osteotomy and mandibular setback with a sagittal splitting ramus osteotomy. The total treatment time was 36 months, including five months of post-surgical observation. After treatment, a stable occlusion was achieved with a Class I molar relationship and a complete open-bite closure. The patient referred remarkable improvements in breathing. Conclusion: Surgically assisted rapid maxillary expansion and Le Fort 1 osteotomy can be regarded as a safe and effective approach for the treatment of skeletal divergence. Long-term observation of the maxillary arch width after retention is of the utmost importance for the maintenance of a successful treatment outcome. Giovanna Perrotti* Michele Izzo* Laura De Vecchi* Aldo B. Giannì** Massimo Del Fabbro***
We studied the in vivo antitumor effects of interleukin-2 (IL-2) and interferon-β(IFN-β) in combination with chemotherapy on murine syngeneic transplantable squamous cell carcinoma, NR-S 1.Tumors were inoculated subcutaneously by injecting NR-S 1 cells into the back of 5-weekold female C 3 H/He mice. The tumor-bearing mice were divided into eight groups, and the following agents and anticancer drugs were administered:(1) control (saline), (2) IL-2+IFN-β, (3) bleomycin (BLM), (4) cyclophosphamide (CY), (5) cisplatinum (CDDP), (6) BLM+IL-2+IFN-β, (7) CY+IL-2+IFN-β, and (8) CDDP+IL-2+IFN-β.Intratumoral injections of saline or IL-2 +IFN-β and intraperitoneal injections of anticancer drugs were continued daily for 14 days. Treatment effects were estimated by measuring the tumor diameter and calculating the survival rate. Fourteen days after treatment, cytotoxic activities (against YAC-1, P815 and NR-S 1 cells) and their splenocyte phenotypes (Thy1.2, L 3 T 4, Lyt-2, and asialo-GM 1) were determined. The excised tumor tissues were also examined histologically.Although tumor size decreased slightly in the IL-2+IFN-β group, the reductions in size were significantly greater in each of the chemotherapy groups (p<0.05). Furthermore, the combination of chemotherapy and IL-2+IFN-β was much more effective in tumor reduction than the corresponding chemotherapy alone. Survival rate was significantly longer in all experimental groups except for the IL-2+IFN-β group. Tumors disappeared completely in two mice in the BLM+IL-2+IFN-β treatment group, which survived for more than 100 days. NK activity was significantly enhanced in mice treated with CDDP, BLM, or CDDP+IL-2+IFN-β. Although low LAK activity and cytotoxic activity against syngeneic NR-S 1 tumor cells were observed in the IL-2+IFN-β grove or the chemotherapy alone group, both of these activities were enhanced when these treatments were combined. Histological examinations disclosed remarkable infiltration of mononuclear cells and tumor necroses in the chemotherapy +IL-2+IFN-β groups. The infiltrated mononuclear cells predominantly expressed Mac-1 or asialo-GM 1 phenotype.These results suggest that the combination of systemic chemotherapy with local administration of IL-2+IFN-β is feasible for cancer therapy. Furthermore, NK cells may play an important role in both antitumor effect and the prolongation of survival.
We studied the in vivo antitumor effects of interleukin-2 (IL-2) and interferon-β(IFN-β) in combination with chemotherapy on murine syngeneic transplantable squamous cell carcinoma, NR-S 1.Tumors were inoculated subcutaneously by injecting NR-S 1 cells into the back of 5-weekold female C 3 H/He mice. The tumor-bearing mice were divided into eight groups, and the following agents and anticancer drugs were administered:(1) control (saline), (2) IL-2+IFN-β, (3) bleomycin (BLM), (4) cyclophosphamide (CY), (5) cisplatinum (CDDP), (6) BLM+IL-2+IFN-β, (7) CY+IL-2+IFN-β, and (8) CDDP+IL-2+IFN-β.Intratumoral injections of saline or IL-2 +IFN-β and intraperitoneal injections of anticancer drugs were continued daily for 14 days. Treatment effects were estimated by measuring the tumor diameter and calculating the survival rate. Fourteen days after treatment, cytotoxic activities (against YAC-1, P815 and NR-S 1 cells) and their splenocyte phenotypes (Thy1.2, L 3 T 4, Lyt-2, and asialo-GM 1) were determined. The excised tumor tissues were also examined histologically.Although tumor size decreased slightly in the IL-2+IFN-β group, the reductions in size were significantly greater in each of the chemotherapy groups (p<0.05). Furthermore, the combination of chemotherapy and IL-2+IFN-β was much more effective in tumor reduction than the corresponding chemotherapy alone. Survival rate was significantly longer in all experimental groups except for the IL-2+IFN-β group. Tumors disappeared completely in two mice in the BLM+IL-2+IFN-β treatment group, which survived for more than 100 days. NK activity was significantly enhanced in mice treated with CDDP, BLM, or CDDP+IL-2+IFN-β. Although low LAK activity and cytotoxic activity against syngeneic NR-S 1 tumor cells were observed in the IL-2+IFN-β grove or the chemotherapy alone group, both of these activities were enhanced when these treatments were combined. Histological examinations disclosed remarkable infiltration of mononuclear cells and tumor necroses in the chemotherapy +IL-2+IFN-β groups. The infiltrated mononuclear cells predominantly expressed Mac-1 or asialo-GM 1 phenotype.These results suggest that the combination of systemic chemotherapy with local administration of IL-2+IFN-β is feasible for cancer therapy. Furthermore, NK cells may play an important role in both antitumor effect and the prolongation of survival.
